Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The potential of the Indian pharmaceutical market to double from the present $8 billion to $15 billion in the next five years led Abbott last week to strike the most richly valued deal for Piramal Healthcare's generic drug businesses, but the action for a share of the Indian market is set to accelerate further as Mylan - the third largest generic company in the world and the largest in the U.S. with sales exceeding $5 billion - is preparing to enter the Indian formulations market

You may also be interested in...



Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned

MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India

Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned

MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India

Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned

The global generics firm will rebrand Matrix, its Indian arm, as "Mylan," as it anticipates launching its prescription products in India under the Mylan label.

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel